Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Endocrinology

What Is the Life Expectancy for Acromegaly Patients?

At a Glance

With modern treatment, people diagnosed with acromegaly can expect to live a normal lifespan. Achieving biochemical control—normalizing growth hormone and IGF-1 levels—is the most critical step to preventing complications and restoring a full, healthy life expectancy.

Being diagnosed with a rare disease like acromegaly is frightening, and one of the most common questions patients have is whether it will shorten their life. The most reassuring fact to know is that with modern treatment, you can expect to live a normal lifespan. When acromegaly is successfully treated and hormone levels are returned to normal—a state called biochemical control—life expectancy is restored to that of the general population [1][2].

The Importance of Biochemical Control

Biochemical control means that your treatments have successfully lowered your growth hormone (GH) and insulin-like growth factor 1 (IGF-1) to healthy levels. Research shows that normalizing these hormones is the single most critical factor in improving longevity [1][3].

Because acromegaly changes the body slowly, many people go undiagnosed for years. This often causes anxiety about whether it is “too late” to prevent long-term damage. The reassuring reality is that taking prompt action to treat the disease after your diagnosis is what matters most. Achieving biochemical control now, regardless of past delays, dramatically improves your long-term health and survival [4].

Risks of Uncontrolled Acromegaly

While the outlook for treated patients is excellent, untreated or uncontrolled acromegaly does carry a higher mortality rate than the general population [5][6]. Chronic exposure to excess GH and IGF-1 places significant stress on the body. The main health risks that can impact life expectancy include:

  • Cardiovascular disease: Excess hormones can enlarge the heart (a condition known as acromegalic cardiomyopathy) and lead to high blood pressure, heart rhythm issues, and heart failure [7][8]. Cardiovascular issues have historically been the most common cause of reduced life expectancy in acromegaly [3].
  • Respiratory complications: Conditions like severe sleep apnea are common and put additional strain on the heart and lungs [9].
  • Metabolic conditions: Developing diabetes is a known risk of acromegaly and independently increases the risk of cardiovascular problems [10].
  • Cancer risk: Long-term exposure to excess IGF-1 is linked to an increased risk of certain cancers, most notably colorectal cancer (often starting as colon polyps) and thyroid cancer [11]. In recent years, as heart disease has become better managed, cancer has emerged as a leading cause of mortality in patients with acromegaly [3][12].

Managing Your Long-Term Health

Because the risks associated with acromegaly are largely driven by these related health conditions (known as comorbidities), managing them is just as important as lowering your GH and IGF-1 levels [13][14]. It is completely normal to feel overwhelmed by the thought of managing multiple medical conditions at once. Building a comprehensive care team—which may include your endocrinologist, a cardiologist, a pulmonologist, and a gastroenterologist—can help lift that burden.

Your care team should proactively monitor your heart health, blood sugar, and sleep quality [3]. Crucially, you will need acromegaly-specific cancer screenings rather than just standard guidelines. This typically means earlier and more frequent colonoscopies, as well as regular thyroid evaluations [3][11]. With a comprehensive treatment plan that addresses both the hormone excess and your overall health, the goal of a full, normal life expectancy is highly achievable [1].

Common questions in this guide

Does acromegaly shorten your life?
With modern treatment and successful management of hormone levels, people with acromegaly can expect to live a normal lifespan. Taking prompt action after your diagnosis is the most important step to protecting your long-term health.
What does biochemical control mean for acromegaly?
Biochemical control means your treatments have successfully lowered your growth hormone and IGF-1 to healthy levels. Reaching this state is the single most critical factor in improving your longevity and preventing further organ damage.
What happens if acromegaly is left untreated?
Untreated acromegaly carries a higher mortality rate due to the constant stress excess hormones place on the body. It increases the risk of serious complications like heart disease, severe sleep apnea, diabetes, and certain cancers.
What kind of cancer screenings do I need if I have acromegaly?
Because excess IGF-1 increases cancer risks, you need acromegaly-specific screenings rather than standard guidelines. This typically involves earlier and more frequent colonoscopies to check for colon polyps, as well as regular thyroid evaluations.
Which specialists should be on my acromegaly care team?
In addition to your primary endocrinologist, a comprehensive care team may include a cardiologist for your heart health, a pulmonologist for sleep apnea, and a gastroenterologist to manage your cancer screenings.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my specific target GH and IGF-1 levels, and what are my current numbers?
  2. 2.What are the next steps in our plan to help me achieve biochemical control as efficiently as possible?
  3. 3.At what age and frequency should I be scheduling my acromegaly-specific colonoscopies and thyroid screenings?
  4. 4.Should I be referred to a cardiologist for a baseline heart evaluation or a pulmonologist for a sleep study?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry.

    Maione L, Brue T, Beckers A, et al.

    European journal of endocrinology 2017; (176(5)):645-655.

    PMID: 28246150
  2. 2

    Acromegaly and Cancer: An Update.

    Danilowicz K, Sosa S

    Archives of medical research 2023; (54(8)):102914 doi:10.1016/j.arcmed.2023.102914.

    PMID: 38007382
  3. 3

    Cardiovascular Disorders Associated With Acromegaly: an Update.

    Sherin RPV, Vietor NO, Usman A, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2024; (30(12)):1212-1219 doi:10.1016/j.eprac.2024.09.014.

    PMID: 39332498
  4. 4

    Remission of Acromegaly: The Sooner the Better.

    Cuny T, Maione L, Störmann S

    Clinical endocrinology 2024; (101(6)):602-604 doi:10.1111/cen.15147.

    PMID: 39373288
  5. 5

    Natural History of Acromegaly: Incidences, Re-operations, Cancers, and Mortality Rates in a National Cohort.

    Wu JC, Huang WC, Chang HK, et al.

    Neuroendocrinology 2020; (110(11-12)):977-987 doi:10.1159/000505332.

    PMID: 31822015
  6. 6

    Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study.

    Esposito D, Ragnarsson O, Granfeldt D, et al.

    European journal of endocrinology 2018; (178(5)):459-469.

    PMID: 29483205
  7. 7

    [Acromegaly and it's cardiovascular implications].

    Cadena-Obando DA, Remba-Shapiro I, Abreu-Rosario CG, Mercado M

    Revista medica del Instituto Mexicano del Seguro Social 2021; (59(1)):73-80 doi:10.24875/RMIMSS.M21000054.

    PMID: 33667046
  8. 8

    Acromegaly and Heart Failure.

    Colao A, Grasso LFS, Di Somma C, Pivonello R

    Heart failure clinics 2019; (15(3)):399-408 doi:10.1016/j.hfc.2019.03.001.

    PMID: 31079698
  9. 9

    A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.

    Giustina A, Barkan A, Beckers A, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(4)) doi:10.1210/clinem/dgz096.

    PMID: 31606735
  10. 10

    Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly.

    Esposito D, Olsson DS, Franzén S, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(9)):2483-2492 doi:10.1210/clinem/dgac400.

    PMID: 35779017
  11. 11

    Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly.

    Freda PU, Bruce JN, Jin Z, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(5)):1247-1257 doi:10.1210/clinem/dgae469.

    PMID: 38986012
  12. 12

    Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis.

    Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS

    European journal of endocrinology 2018; (179(1)):59-71.

    PMID: 29764907
  13. 13

    Acromegaly and Cardiovascular Disease: Associated Cardiovascular Risk Factors, Cardiovascular Prognosis, and Therapeutic Impact.

    Iglesias P

    Journal of clinical medicine 2025; (14(6)) doi:10.3390/jcm14061906.

    PMID: 40142714
  14. 14

    Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

    Pivonello R, Auriemma RS, Grasso LF, et al.

    Pituitary 2017; (20(1)):46-62 doi:10.1007/s11102-017-0797-7.

    PMID: 28224405

This page provides educational information about acromegaly and life expectancy. Always consult your endocrinologist or medical team for personalized advice regarding your prognosis, hormone targets, and treatment plan.

Get notified when new evidence is published on Acromegaly.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.